Urgent FDA Priority Review Voucher Deadline Approaches: Implications for Pediatric Drug Development

Thanksgiving Week Update

Happy Thanksgiving week! If you’re traveling, safe travels.

• Regular publishing will resume Monday.

Situational Update: President-elect Trump has appointed James Braid as the White House legislative affairs director. Braid was previously the deputy chief of staff to Vice President-elect JD Vance in the Senate.

1 Big Thing: Priority Review Voucher Deadline

The FDA’s priority review voucher program needs reauthorization by December. This program helps develop treatments for rare pediatric diseases. If it is not reauthorized, these developments may be at risk.

Why This Matters: Patient advocates and pharmaceutical companies view this program as essential. It provides incentives for drugmakers to create treatments for rare diseases, allowing faster FDA evaluations. However, some critics argue it is a subsidy for drug companies.

Voices in the Discussion: Terry Wilcox from Patients Rising highlighted that the program encourages companies to invest in neglected diseases. He warns that failing to renew it could hinder progress in improving patient access to therapies.

Current Status: The program was set to expire on September 30 but received a temporary extension. The new deadline is December 20, the same day as a broader government funding agreement expires.

Legislative Context: There have been discussions about including the reauthorization in the pandemic preparedness bill (PAHPA) or as part of an end-of-year legislative package. Costs for the program are estimated to be low, mainly for administration.

Potential Obstacles: HELP Committee Chair Bernie Sanders opposes the program, seeing it as a support for drug manufacturers. His views add tension to the reauthorization effort. During recent committee discussions, some lawmakers questioned the program’s effectiveness but still supported it.

Stay tuned for updates on the outcome.